RxDoctor Payments Data

Robert Gerald, MD

Ophthalmology · Amarillo, TXNPI 1154384253

Payments from drug & device makers

$840in general payments, 2019–2025

Across 58 payments — averaging $14.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$401
  • Bausch & Lomb Americas Inc.$248
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$72
  • Aerie Pharmaceuticals, Inc.$50
  • Novartis$50
  • Alcon$19

What the payments were for

  • Food & beverage$840100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$840 in reported general payments places this provider in the 30th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$140,629
Medicare patients
491
Services billed
1,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine337$243,195
Cyclosporine134$52,535
XiidraLifitegrast28$21,814
RocklatanNetarsudil Mesylat/Latanoprost38$15,395
Prednisolone Acetate137$8,682
CombiganBrimonidine Tartrate/Timolol30$5,968
Alphagan PBrimonidine Tartrate28$5,660
LumiganBimatoprost11$4,760
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$2,603
Travoprost12$1,080
Dorzolamide Hcl44$817
Latanoprost74$530
Doxycycline Hyclate16$273
Timolol Maleate23$255
Acetazolamide11$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Alphagan P, Lumigan$401$259,583406 claims
Bausch & Lomb Americas Inc.Xiidra$248$21,81428 claims
Aerie Pharmaceuticals, Inc.Rocklatan$50$15,39538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →